VASH1-AS1: A Potential Drug Target and Biomarker (G100506603)

Target Name: VASH1-AS1

NCBI ID: G100506603

VASH1-AS1

Other Name(s): VASH1 antisense RNA 1 | VASH1 antisense RNA 1, transcript variant 1

VASH1-AS1: A Potential Drug Target and Biomarker

VASH1 (Virsta-AS1) is a protein that is expressed in various tissues of the body, including the brain. It is a member of the S1P family of proteins, which are involved in various cellular processes, including cell signaling. One of the functions of VASH1 is to regulate the activity of ion channels, which are responsible for the flow of electrical signals through cells. This protein has been shown to play a role in the regulation of pain perception and neurotransmitter release, making it a potential drug target.

The research on VASH1 has been ongoing for several years, and there is a growing interest in this protein as a potential drug target. Several studies have shown that VASH1 can interact with various drugs, including small molecules and antibodies. These interactions may have implications for the use of these drugs in treating various diseases, including pain, neurodegenerative diseases, and psychiatric disorders.

One of the potential benefits of targeting VASH1 is its potential to modulate pain perception. Pain can be a symptoms of various diseases, including neurodegenerative diseases, cancer, and trauma. Currently, there are few effective treatments available for relieving pain, and many patients suffer from chronic pain that can be difficult to manage. Targeting VASH1 could potentially lead to the development of new pain medications that can effectively treat pain.

Another potential benefit of VASH1 is its role in neurotransmission. Neurotransmitters are molecules that are used by the brain to communicate with other cells. These molecules play a crucial role in the regulation of various brain functions, including mood, attention, and pain perception. VASH1 has been shown to be involved in the regulation of neurotransmitter release, which could make it a potential target for drugs that target neurotransmitter systems.

In addition to its potential as a drug target, VASH1 has also been shown to be a potential biomarker. The regulation of ion channels is a critical process that is involved in the function of many cells. This regulation is often monitored by various proteins, including VASH1. By studying the regulation of ion channels by VASH1, researchers may be able to gain insights into the underlying mechanisms of many diseases. This could potentially lead to the development of new treatments for a wide range of diseases.

Targeting VASH1 could also have potential implications for the development of new psychiatric disorders. The regulation of ion channels is a critical process that is involved in the function of many neurons, which are responsible for the production and transmission of neurotransmitters. Dysregulation of ion channels has been implicated in the development of various psychiatric disorders, including depression, anxiety, and schizophrenia. Targeting VASH1 could potentially lead to the development of new treatments for these disorders.

In conclusion, VASH1 is a protein that has been shown to play a role in the regulation of various cellular processes, including cell signaling and neurotransmission. Its potential as a drug target and biomarker make it an attractive target for researchers to study. Further studies are needed to fully understand the role of VASH1 in cellular processes and its potential as a drug and biomarker.

Protein Name: VASH1 Antisense RNA 1

The "VASH1-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about VASH1-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets